Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma October 29, 2026 10:30 AM EDT Birgitte Rono - Chief Scientific Officer & COO Birgitte RonoChief Scientific Officer & COO I'm Birgitte Rono, CSO and COO at Evaxion. So on behalf…
Title: Selective targeting of integrins αvβ8 and αvβ1 improves anti-tumor responses mediated by immune checkpoint inhibition Friday, November 6, 2026, 12:15 – 1:45 p.m. and 5:30 – 7:30 p.m. Mountain Time Title: Plasma biomarkers of immune activation predict sensitization to immune checkpoint inhibition (ICI) in patients with advanced…
— Modified FOLFIRINOX failed to improve disease-free survival in stage III disease Intensified adjuvant chemotherapy did not improve disease-free survival (DFS) compared with standard chemotherapy in patients with high-risk stage III colon cancer, the phase III IROCAS trial showed. While overall…
Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCIâs Surveillance, Epidemiology and End... Thank you for visiting nature.com. You…
Pancreatic cancer is incredibly difficult to shake. Even after surgery or chemotherapy, the disease may never go away completely. By some estimates, malignant tumors in the pancreas can recur in up to 80 percent of patients. Those with certain gene mutations…
Many patients with skin cancer who were treated with immune checkpoint inhibition experienced long-term side effects, although some resolved over time, research showed. Chronic immune-related side effects were common in patients with skin cancer who were treated with postsurgical Opdivo…
First late effects study since new treatments were introduced found high prevalence of hearing loss, growth failure, underweight and lung disease Globally, neuroblastoma accounts for 8–10 percent of childhood cancers. It is generally diagnosed at a median age of 17–18 months, with…
Cells regulate RNA and protein abundance through a multi-layered process. Excitingly, peeling back one layer has revealed additional layers below, highlighting the complex nature of this process. For... Gene specific alternative polyadenylation can reduce tumor growth The process of mRNA…
CEL-SCI Corporation CEO Geert Kersten joined Steve Darling from Proactive to discuss new tumor-response and safety analyses from the company’s completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy for head and neck cancer. The findings were presented…
CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation…
Treatments that turn the immune system on cancer: checkpoint inhibitors, CAR-T and other cell therapies for cancer, and personalised mRNA cancer vaccines.
An article joins this feed when it matches these terms. Each one is also a search of its own.